YGEN.L Regulatory News (YGEN)

4 November 2014

Premaitha Health PLC

("the Company")

AGM Statement

Premaitha Health PLC, a molecular diagnostics company employing next generation DNA analysis technology to develop molecular diagnostic products, is pleased to provide the following statement ahead of today's AGM.

Following the update provided at the General Meeting on 3 July 2014, the Company has made further progress in the development and preparations for commercialisation of its lead product - the IONA® Test.

The development and launch preparations of the IONA® non-invasive prenatal screening test remain on schedule and in line with the timetable set out in the admission document. The Company has received positive feedback on its quality systems and regulatory strategy, and the IONA® Test has performed well in verification studies.

Recruitment of commercialisation and technical support teams is ongoing and the Company has presented the test at a number of international fetal medicine and medical genetic conferences in Europe, USA and Australia. There has been positive interest in the product from customers in the UK, Europe, Asia and Australasia from both private and publicly funded clinical laboratories.

The directors believe that the IONA® Test remains on target to be the first regulated CE marked in vitro diagnostic product in the rapidly growing market for non-invasive prenatal screening.

The Company looks forward to updating shareholders with further announcements in due course.

-Ends-